A detailed history of State Street Corp transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, State Street Corp holds 609,673 shares of ATNM stock, worth $1.09 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
609,673
Previous 550,845 10.68%
Holding current value
$1.09 Million
Previous $4.31 Million 4.59%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$6.56 - $9.89 $385,911 - $581,808
58,828 Added 10.68%
609,673 $4.51 Million
Q1 2024

May 15, 2024

BUY
$5.0 - $9.2 $220,015 - $404,827
44,003 Added 8.68%
550,845 $4.31 Million
Q4 2023

Feb 14, 2024

SELL
$4.02 - $6.08 $64,922 - $98,192
-16,150 Reduced 3.09%
506,842 $2.57 Million
Q3 2023

Nov 14, 2023

BUY
$5.91 - $7.37 $244,017 - $304,299
41,289 Added 8.57%
522,992 $3.1 Million
Q2 2023

Aug 14, 2023

BUY
$7.15 - $9.39 $2.76 Million - $3.62 Million
385,688 Added 401.7%
481,703 $3.57 Million
Q1 2023

May 15, 2023

BUY
$8.51 - $14.26 $65,527 - $109,802
7,700 Added 8.72%
96,015 $907,000
Q4 2022

Feb 14, 2023

BUY
$7.05 - $14.41 $92,355 - $188,771
13,100 Added 17.42%
88,315 $940,000
Q2 2022

Aug 15, 2022

BUY
$4.71 - $7.11 $57,462 - $86,742
12,200 Added 19.36%
75,215 $362,000
Q1 2022

May 16, 2022

BUY
$4.57 - $6.4 $32,095 - $44,947
7,023 Added 12.54%
63,015 $322,000
Q4 2021

Feb 14, 2022

BUY
$6.01 - $8.8 $4,207 - $6,160
700 Added 1.27%
55,992 $337,000
Q2 2021

Aug 16, 2021

BUY
$7.01 - $8.63 $387,596 - $477,169
55,292 New
55,292 $437,000

Others Institutions Holding ATNM

About Actinium Pharmaceuticals, Inc.


  • Ticker ATNM
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,184,700
  • Market Cap $44.8M
  • Description
  • Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...
More about ATNM
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.